Phase II III in UC patients
Research payments
$959,391
Through program year 2023, $959,391 in research payments was reported against Phase II III in UC patients, across 110 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..
- Paid by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $2,533 | 1 |
| 2022 | Research | $15,750 | 1 |
| 2021 | Research | $30,911 | 7 |
| 2020 | Research | $364,326 | 30 |
| 2019 | Research | $545,871 | 71 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jeffry Katz Beachwood, OH Named on 5 payments
- Udayakumar Navaneethan Orlando, FL Named on 4 payments
- G Verne New Orleans, LA Named on 3 payments
- Themistocles Dassopoulos Dallas, TX Named on 3 payments
- Philip Ginsburg Hamden, CT Named on 3 payments
- Maria Abreu Miami, FL Named on 3 payments
- Uma Murthy Syracuse, NY Named on 3 payments
- Kofi Clarke Hershey, PA Named on 3 payments
- Timothy Ritter Southlake, TX Named on 3 payments
- Michael Georgetson Sayre, PA Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.